scholarly journals Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia

2019 ◽  
Vol 3 (20) ◽  
pp. 3033-3037 ◽  
Author(s):  
Nicola Gökbuget ◽  
Hagop M. Kantarjian ◽  
Monika Brüggemann ◽  
Anthony S. Stein ◽  
Ralf C. Bargou ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Prognostic Factor ◽  
B Cell ◽  
Lymphoblastic Leukemia ◽  
Molecular Response ◽  
Cell Precursor ◽  
Key Points

Key Points MRD response has value as a prognostic factor for blinatumomab treatment in R/R B-cell precursor ALL. MRD response was associated with better outcomes in terms of OS and RFS in blinatumomab-treated R/R ALL.

scholarly journals IKZF1 DELETIONS ARE INDEPENDENT PROGNOSTIC FACTOR IN PEDIATRIC B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

2016 ◽  
Vol 11 (4) ◽  
pp. 32-48
Author(s):  
G. A. Tsaur ◽  
A. Е. Druy ◽  
A. G. Solodonikov ◽  
A. M. Popov ◽  
A. P. Shapochnik ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Prognostic Factor ◽  
B Cell ◽  
Lymphoblastic Leukemia ◽  
Independent Prognostic Factor ◽  
Cell Precursor

scholarly journals EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications

Blood ◽  
2016 ◽  
Vol 127 (18) ◽  
pp. 2214-2218 ◽  
Author(s):  
Claire Schwab ◽  
Sarra L. Ryan ◽  
Lucy Chilton ◽  
Alannah Elliott ◽  
James Murray ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
B Cell ◽  
Lymphoblastic Leukemia ◽  
Clinical Implications ◽  
Genetic Profile ◽  
Cell Precursor ◽  
Key Points

Key Points EBF1-PDGFRB fusion accounts for ∼0.5% of B-cell precursor acute lymphoblastic leukemia and 2.7% of the B-other subtype. EBF1-PDGFRB-positive patients are MRD positive and are slow early responders who respond to imatinib.

scholarly journals B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment

Blood ◽  
2015 ◽  
Vol 126 (21) ◽  
pp. 2404-2414 ◽  
Author(s):  
Roel Polak ◽  
Bob de Rooij ◽  
Rob Pieters ◽  
Monique L. den Boer
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
B Cell ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Lymphoblastic Leukemia ◽  
Leukemia Cells ◽  
Cell Precursor ◽  
Tunneling Nanotubes ◽  
Key Points ◽  
Tunneling Nanotube

Key Points Primary BCP-ALL cells use tunneling nanotubes to signal to mesenchymal stromal cells and thereby trigger cytokine secretion. Inhibiting tunneling nanotube signaling is a promising approach to induce apoptosis and sensitize BCP-ALL cells toward prednisolone.

scholarly journals Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?

2017 ◽  
Vol 1 (19) ◽  
pp. 1473-1477 ◽  
Author(s):  
Claire Schwab ◽  
Karin Nebral ◽  
Lucy Chilton ◽  
Cristina Leschi ◽  
Esmé Waanders ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
B Cell ◽  
Lymphoblastic Leukemia ◽  
Cell Precursor ◽  
Poor Outcome ◽  
Key Points

Key Points Intragenic PAX5 amplification defines a novel, relapse-prone subtype of B-cell precursor acute lymphoblastic leukemia with a poor outcome.

scholarly journals Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia

Blood ◽  
2018 ◽  
Vol 131 (26) ◽  
pp. 2929-2942 ◽  
Author(s):  
Fan Wang ◽  
Salih Demir ◽  
Franziska Gehringer ◽  
Clarissa D. Osswald ◽  
Felix Seyfried ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
B Cell ◽  
Lymphoblastic Leukemia ◽  
Preclinical Model ◽  
Cell Precursor ◽  
Key Points

Key Points FOXO1 activity is essential for growth and maintenance of BCP-ALL. Inhibition of FOXO1 reduces leukemia load and prolongs survival in a preclinical model of BCP-ALL.

Sign in / Sign up

Export Citation Format

Share Document